奧鋭特(605116.SH):上半年淨利潤1.89億元 同比增長96.66%
格隆匯8月28日丨奧鋭特(605116.SH)公佈半年度報吿,2024年上半年,公司實現營業收入7.31億元,較去年同期增長32.21%;實現歸屬於上市公司股東的淨利潤1.89億元,較去年同期增長96.66%。公司本期營業收入和歸屬於上市公司股東的淨利潤及歸屬於上市公司股東的扣除非經常性損益的淨利潤較去年同期實現大幅增長,主要是因為:1、公司持續專注主業,優勢原料藥持續推進,銷售穩健增長;2、製劑產品逐步上量,市場拓展成效進一步體現,與去年同期相比,是全新的領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.